| Theme | Virtual Endoscopy -- Present Status and Perspective | |
|---|---|---|
| Title | Current Status of Virtual Colonoscopy in the United States-As a Colorectal Cancer Screening Test | |
| Publish Date | 2002/06 | |
| Author | Shoryoku Hino | Digestive Disease Center, Medical University of South Carolina, USA |
| Author | Tara Noone | Digestive Disease Center, Medical University of South Carolina, USA |
| Author | Robert Chen | Digestive Disease Center, Medical University of South Carolina, USA |
| Author | Patric Connor | Digestive Disease Center, Medical University of South Carolina, USA |
| Author | Robert Hawes | Digestive Disease Center, Medical University of South Carolina, USA |
| Author | Peter B.Cotton | Digestive Disease Center, Medical University of South Carolina, USA |
| Author | Guruparasad P.Aithal | Department of Gastroenterology, Qeen's Medical Center, Nottingham, UK |
| Author | Niall Breslin | Digestive Disease Center, Medical University of South Carolina, USA |
| Author | Bora Gumstop | Department of lnternal Medicine, Albany Medical Center, NY, USA |
| Author | Shigeru Matsumoto | Department of Radiology, The Jikei University School of Medicine |
| Author | Kazuki Sumiyama | Department of Endoscopy, The Jikei University School of Medicine |
| Author | Hiroshi Arakawa | Department of Endoscopy, The Jikei University School of Medicine |
| Author | Hisao Tajiri | Department of Endoscopy, The Jikei University School of Medicine |
| [ Summary ] | Virtual colonoscopy (VC) has been tested as a tool for colorectal cancer screening in the United States. In most of the prospective studies, only patients at high risk for colorectal cancer were included. Although public perception is favorable towards virtual colonoscopy, the tolerance of patients towards VC is similar to that of colonoscopy. Studies to date have suggestedless cost efficacy in using VC in comparison with using colonoscopy as a screening tool for colorectal cancer. Further improvements in technology, decreases in the cost of VC and large scale clinical trials, performed on the average risk screening population, are required to further define the role of VC in screening for colorectal cancer. | |